Immunome IMNM Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Immunome (IMNM) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $0 in Q1 2026.
- How has Immunome's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- Immunome's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 100.0% year-over-year, from $15M to $0.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.